Carbapenem market is majorly driven by the rising prevalence of infectious diseases such as urinary tract infections (UTIs), intra-abdominal infections, & bacterial meningitis and the increasing movement of generic product companies.
Carbapenem market is majorly driven by the rising prevalence of infectious diseases such as urinary tract infections (UTIs), intra-abdominal infections, & bacterial meningitis and the increasing movement of generic product companies. Urinary tract infections (UTIs) are one of the most common infections that lead to emergency or clinic visits or indoor admissions across the world. Carbapenems such as Meropenem-Vaborbactam are approved by FDA for use in such complicated urinary tract infections.
Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/39831
The widespread infections from the community with these organisms are likely to lead to a dramatic increase in empiric carbapenem use. Newer oral carbapenems such as tebipenem have also proven to be effective against the cUTI in clinical trials. Tebipenem also has the added advantage of being effective in lower cUTIs. It also reduces the potential complications and hospitalization costs which gives carbapenems an added advantage over other classes of antibiotics.
Branded products were originally discovered by a company and hold the majority share of the market. There are various branded carbapenems available in the market such as Invanz marketed by Merck & Co, Vabomere by Melinta Therapeutics and Merrem by Pfizer Inc. These carbapenems are effective against a broad spectrum of gram-positive and negative bacteria. Moreover, advantages such as less development of resistance and high tolerability are expected to boost the market of branded products.
Asia Pacific is also anticipated to exhibit strong growth momentum during the forecast period. This growth can be attributed to several factors, such as the growing geriatric population, poor access to healthcare facilities, and dense urbanization. Asia-pacific has a high incidence of community-acquired pneumonia which has become an economic burden in the region. Moreover, firms with generic carbapenem drugs are also expanding their portfolio in the region. Asia Pacific is estimated to own the highest share of the market, due to an improving economic scenario, rising disposable income, and a large patient pool. In February 2022, Sumitomo Dainippon Pharma Co., Ltd partnered with its parent business Sumitomo Dainippon Pharma Co., Ltd to initiate phase 1 research for KSP-1007.
In September 2022, GSK plc., and Spero Therapeutics entered into an exclusive licensing agreement for the commercialization of a late-stage antibiotic Tebipenem HBr worldwide except in Japan and some Asian countries. Therefore, initiatives undertaken by key players such as collaboration, agreement, and partnership for the development and commercialization of new carbapenems to treat patient with bacterial infections is projected to fuel the market growth.
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/39831
Growth Drivers:
- The demand for carbapenem-based medicines for pneumonia and other infections will rise as the frequency of hospital-acquired bacterial illnesses rises.
- The market will be driven by a high demand for carbapenem-based antibiotics in hospitals prior to surgery.
- With the patent expiration of branded entrapenem and the launch of generic antibiotics, sales of carbapenem-based antibiotics will increase.
Key restraints:
- Stringent regulatory process for drug approval is hampering the sales of carbapenem-based antibiotics.
- Rise in antibiotic resistant bacterial strains and tedious procedure for developing new carbapenem based antibiotics will hamper the market growth.
Key Players
- Menarini Group
- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd
- Lupin
- Kopran Limited
- Aurobindo Pharma
- Daewoong Pharmaceuticals Co., Ltd.
- Shenzhen Haibin Pharmaceutical Co. Ltd.
- Merck & Co., Inc.
Market Segmentation
- Product Type
- Branded Products
- Imipenem
- Meropenem
- Ertapenem
- Doripenem
- Biapenem
- Panipenem
- Others
- Generic Products
- Branded Products
- By Application
- Urinary Tract Infections (UTIs)
- Bloodstream Infections
- Intra-abdominal Infections
- Pneumonia
- Acute Pelvic Infections
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
- By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa (MEA)
Click Here to View Full Report Table of Contents
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/39831
You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333
Blog: https://www.novaoneadvisor.com/
Blog: https://qyresearchmedical.com/